| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.19▼ | 1.20▼ | 1.20▼ | 1.15▼ | 1.33▼ |
| MA10 | 1.24▼ | 1.24▼ | 1.24▼ | 1.20▼ | 1.37▼ |
| MA20 | 1.25▼ | 1.28▼ | 1.29▼ | 1.34▼ | 1.41▼ |
| MA50 | 1.37▼ | 1.46▼ | 1.46▼ | 1.39▼ | 1.33▼ |
| MA100 | 1.47▼ | 1.43▼ | 1.42▼ | 1.41▼ | 1.75▼ |
| MA200 | 1.42▼ | 1.43▼ | 1.44▼ | 1.40▼ | 2.70▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.006▼ | -0.006▼ | -0.008▼ | -0.025▼ | -0.032▼ |
| RSI | 18.640▼ | 20.549▼ | 21.691▼ | 30.674▼ | 40.539▼ |
| STOCH | 7.692▼ | 21.234 | 19.792▼ | 11.265▼ | 20.327 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -81.395▼ | -88.060▼ |
| CCI | -240.860▼ | -243.146▼ | -234.110▼ | -101.968▼ | -219.886▼ |
|
Monday, July 27, 2026 02:24 PM
Merck (NYSE:MRK) moves late-stage cancer data, subcutaneous immunotherapy and HIV work forward as its early-August quarterly update nears in the US healthcare sector.
|
|
Monday, July 27, 2026 01:56 AM
Merck (NYSE:MRK) advances as defensive rotation, oncology and vaccine demand, and a midweek Federal Reserve rate decision keep large-cap healthcare in view this week.
|
|
Sunday, July 19, 2026 02:06 AM
Merck (NYSE:MRK) received FDA approval for Lipfendra (enlicitide), the first oral PCSK9 cholesterol-lowering drug. Lipfendra introduces an oral option for patients who have so far relied on injectable ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 31/07/26 | 1.15 | 1.20 | 1.11 | 1.13 | 37,436 |
| 30/07/26 | 1.11 | 1.14 | 1.05 | 1.12 | 72,414 |
| 29/07/26 | 1.1883 | 1.21 | 1.11 | 1.11 | 39,199 |
| 28/07/26 | 1.22 | 1.22 | 1.18 | 1.18 | 20,186 |
| 27/07/26 | 1.21 | 1.25 | 1.20 | 1.22 | 42,251 |
| 24/07/26 | 1.27 | 1.3186 | 1.21 | 1.22 | 59,235 |
| 23/07/26 | 1.23 | 1.3082 | 1.2216 | 1.27 | 14,250 |
| 22/07/26 | 1.26 | 1.285 | 1.24 | 1.24 | 42,583 |
| 21/07/26 | 1.28 | 1.32 | 1.27 | 1.27 | 26,162 |
| 20/07/26 | 1.29 | 1.32 | 1.28 | 1.28 | 58,339 |
|
|
||||
|
|
||||
|
|